Vivani Medical Inc. has released a presentation detailing its ongoing developments and future plans. The company is focused on creating ultra long-acting, miniature drug implants aimed at treating chronic diseases. Their NanoPortal platform technology is designed to improve medication adherence and tolerability. Key programs highlighted include NPM-115, a high-dose exenatide implant, and NPM-139, a semaglutide implant, both under development for chronic weight management in obese and overweight individuals with potential once or twice-yearly dosing. Additionally, the pipeline features NPM-119, an exenatide implant for type 2 diabetes, intended for twice-yearly dosing. Vivani anticipates significant milestones in 2025, including the completion of the First-in-human LIBERATE-1 trial and progress in the NPM-139 program. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.